key: cord-0300543-gf8rxlip
authors: Buil, Jochem B.; Oliver, Jason D.; Law, Derek; Baltussen, Tim; Zoll, Jan; Hokken, Margriet W.J.; Tehupeiory-Kooreman, Marlou; Melchers, Willem J.G.; Birch, Mike; Verweij, Paul E.
title: Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance
date: 2021-11-17
journal: bioRxiv
DOI: 10.1101/2021.11.16.468917
sha: cdd91f846fb145549846fd88994228ff1630955e
doc_id: 300543
cord_uid: gf8rxlip

Olorofim (F901318) is a new antifungal currently under clinical development that shows both in vitro and in vivo activity against a number of filamentous fungi including Aspergillus fumigatus. In this study we screened A. fumigatus isolates for intrinsic olorofim-resistant A. fumigatus and evaluated the ability of A. fumigatus to acquire an olorofim-resistant phenotype. No intrinsic resistance was found in 975 clinical A. fumigatus isolates. However, we found that isolates with increased olorofim MICs (> 8 mg/L) could be selected using a high number of conidia and olorofim exposure under laboratory conditions. Assessment of the frequency of acquired olorofim resistance development of A. fumigatus was shown to be higher than for voriconazole but lower than for itraconazole. Sequencing the PyrE gene of isogenic isolates with olorofim MICs of >8 mg/L identified various amino acid substitutions with a hotspot at locus G119. Olorofim was shown to have reduced affinity to mutated target protein dihydroorotate dehydrogenase (DHODH) and the effect of these mutations were proven by introducing the mutations directly in A. fumigatus. We then investigated whether G119 mutations were associated with a fitness cost in A. fumigatus. These experiments showed a small but significant reduction in growth rate for strains with a G119V substitution, while strains with a G119C substitution did not exhibit a reduction in growth rate. These in vitro findings were confirmed in an in vivo pathogenicity model. Importance Olorofim represents an important new treatment option for patients with difficult to treat invasive fungal infections, including triazole-resistant A. fumigatus infection. Our study provides insights into one resistance mechanism and the potential dynamics of olorofim resistance, which will help to prevent and manage resistance selection. Such insights are critical to antifungal stewardship and to safeguard its prolonged use in clinical practice.

Olorofim (F901318) is a new antifungal currently under clinical development that shows both 18 in vitro and in vivo activity against a number of filamentous fungi including Aspergillus 19 fumigatus. In this study we screened A. fumigatus isolates for intrinsic olorofim-resistant A. 20 fumigatus and evaluated the ability of A. fumigatus to acquire an olorofim-resistant 21 phenotype. No intrinsic resistance was found in 975 clinical A. fumigatus isolates. However, 22

we found that isolates with increased olorofim MICs (> 8 mg/L) could be selected using a 23 high number of conidia and olorofim exposure under laboratory conditions. Assessment of 24 the frequency of acquired olorofim resistance development of A. fumigatus was shown to be 25 higher than for voriconazole but lower than for itraconazole. Sequencing the PyrE gene of 26 isogenic isolates with olorofim MICs of >8 mg/L identified various amino acid substitutions 27 with a hotspot at locus G119. Olorofim was shown to have reduced affinity to mutated target 28 protein dihydroorotate dehydrogenase (DHODH) and the effect of these mutations were 29 proven by introducing the mutations directly in A. fumigatus. We then investigated whether 30 G119 mutations were associated with a fitness cost in A. fumigatus. These experiments 31 showed a small but significant reduction in growth rate for strains with a G119V substitution, 32 while strains with a G119C substitution did not exhibit a reduction in growth rate. These in 33 vitro findings were confirmed in an in vivo pathogenicity model. 34 35 Importance (61 words) 36

It is estimated that around 250,000 people worldwide suffer from invasive aspergillosis 43 annually (1). Patients at risk include those with neutropenia and in recent years cases have 44 been increasingly observed in intensive care unit patients, including those with severe 45 influenza and coronavirus infection (2-6). The triazoles voriconazole and isavuconazole are 46 the recommended first line agents for the management of invasive aspergillosis (7, 8) . The 47 use of other registered antifungal agents such as liposomal amphotericin B is limited due to 48 toxicity while the echinocandins exhibit lower efficacy against Aspergillus compared to the 49 triazoles. Furthermore, the triazoles are currently the only agents that can be administered 50 orally. However, the use of triazoles is threatened by the emergence of azole resistance in 51

Aspergillus fumigatus, (9) which has now been reported globally (10, 11). Voriconazole 52 resistance in A. fumigatus infection was associated with a near doubling of mortality at day 53 42 compared to voriconazole susceptible infection in patients that were treated with 54 voriconazole (12). Azole resistance is mainly driven by environmental exposure of A. 55 fumigatus to azole fungicides, which selects for fungicide resistance mutations that confer 56 cross resistance to medical triazoles. In regions with environmental resistance, any patient 57 may present with azole-resistant invasive aspergillosis that complicates diagnosis and 58 successful therapy. Thus, there is an urgent need for new antifungal agents with efficacy 59 against both azole-susceptible and azole-resistant A. fumigatus infection. 60

Talaromyces species (14, 30) . The in vitro activity was confirmed in in vivo models for 71 pulmonary aspergillosis with azole-susceptible and azole-resistant isolates of A. fumigatus 72 (14, 22) , in a murine model of disseminated A. terreus aspergillosis (31), a murine model of 73 chronic granulomatous disease infected with A. fumigatus, A. nidulans, and A. tanneri (18) 74 and in a murine model of central nervous system coccidioidomycosis (28). 75

Antifungal drug resistance may develop through genetic variation that is created by the 76 fungus to enable its adaptation to stress factors in its environment. Although drug exposure 77

is not relevant to the development of resistance mutations per se, antifungal drug selection 78 pressure is critical to create dominance of resistant cells within a population of fungal cells. 79

The risk of resistance selection to a new class of antifungal drugs such as the orotomides will 80 depend on the frequency of spontaneous mutations that confer an orotomide-resistant 81 phenotype and the extent of selection pressure through patient therapy. A. fumigatus sensu strictu (32). As we suspected selection of a colony with a spontaneous 103 olorofim resistance mutation, we tried to replicate this observation. Inoculation of >1x10 9 104 spores of three A. fumigatus isolates (AZN8196, V052-35 and V139-36) on three 90 mm petri 105 dishes with RPMI1620 agar supplemented with 2% glucose containing 0.5 mg/L olorofim, 106 two olorofim-non-wildtype A. fumigatus colonies were retrieved from parental strain AZN8196 107 (AZN8196_OLR1 and AZN8196_OLR2), three from V052-35 (V052-35_OLR1 to 108 V052_OLR3) and 11 from V139-36 (V139-36_OLR1 to V139-36-OLR11). 109

asexual sporulation. Six A. fumigatus isolates (ATCC 204305, AZN8196, V052-35 111 between 1.2 x 10 -6 and 3.3 x 10 -8 and the mean voriconazole resistance frequency was 116 between 1.8 x 10-8 and 2.0 x 10-10 . Overall, the frequency of resistance was higher for 117 itraconazole compared to olorofim, while voriconazole had the lowest frequency of 118 resistance. The frequency of resistance of olorofim was significantly lower than itraconazole 119 for strains AZN8196 and V254-51, while the frequency was not significantly lower for strains 120 ATCC204305, V139-36 and V180-37. The frequency of voriconazole resistance was 121 significantly lower compared with olorofim for strains ATCC204305, AZN8196, V139-36 and 122 V254-51, while no significant differences were observed for strain V180-37. The second 123 independent resistance frequency analysis using isolate Af293, which was cultured on yeast 124 nitrogen base agar with glucose supplemented with 0.25 mg/L olorofim resulted in a mean 125 frequency of olorofim resistance of 1.7x 10 -9 , a rate comparable to the above experiments. A 126 total of 11 isolates were retrieved from parent strain Af293 of which 10 had an olorofim MIC 127 of >8 mg/L while one had a MIC of 0.25 mg/L (Table S1) . 128 129 Sequencing of pyrE identifies a hotspot for olorofim resistance at Gly119. The target of 130 olorofim has been identified as the pyrimidine biosynthetic enzyme DHODH, which in A. 131 fumigatus is encoded by the pyrE gene. When sequencing the full pyrE gene of olorofim 132 strains retrieved from parent strain Af293, we found mutations at locus G119 in 10 of 11 133 sequenced olorofim-non-wildtype isolates. A single isolate with an olorofim MIC of 0.25 mg/L 134 had a pyrE sequence identical to the parent Af293 strain. Subsequent analysis of a subset of 135 39 isolates from the resistance frequency analysis, showed that mutations that resulted in an 136 amino acid substitution at G119 were present in 38/39 isolates. In total 7 isolates had a 137 G119A amino acid substitution, while we found G119C (21 isolates), G119F (1 isolate), 138 G119Y (1 isolates), G119S (11 isolates), and G119V (7 isolates) amino acid substitutions in 139 the other isolates. One olorofim-resistant isolate harbored a H116P amino acid substitution in 140 the PyrE gene ( Table 2) .

We investigated the effect that selected 142 mutations at G119 had on the ability of olorofim to inhibit recombinant A. fumigatus DHODH. 143

Recombinant DHODH with the amino acid substitutions G119A, G119V G119S and G119C 144 showed significantly higher IC 50 values for olorofim compared to wildtype DHODH (Figure 2) . 145

The substitutions at G119 thus result in decreased inhibition of A. fumigatus DHODH by 146 olorofim, confirming the olorofim resistance mechanism. curves are shown in Figure 3 . The mean radial growth at day 5 of AZN8196_OLR1 (carrying 163 the G119V mutation) was 30.7 mm, which was significantly different to the wildtype parent 164 strain AZN8196 which had a mean growth of 40.0 mm (p<0.001). The mean radial growth of 165 AZN8196_OLR2 (G119C) was 35.8 mm, also slightly reduced compared to strain AZN8196 166 but not significantly (P=0.06). The mean growth at day 5 was 42.7 mm for Af293, which was 167 not significantly different compared with the mean growth at day of strain Af293_OLR7 168 (G119C), which had a mean growth 43.2 mm. The mean 5-day growth of Af293_OLR5 169 (G119S) was slightly decreased compared to parent at 39.5 mm (p=0.0039). Once more the 170 glycine to valine mutation had the greater effect on growth with Af293_OLR9 growing 28.8 171 mm, 14.4 mm less that the parental strain (p=0.0010). Thus, in two different A. fumigatus 172 strains the G119V mutants grew significantly more slowly than the parental strain ( Figure 3) . 173

Although the radial growth rate experiments did not reveal significant fitness cost for two of 175 the tested isolates, we wanted to confirm these observations in a neutropenic murine Whilst the other mutants tested appeared as virulent as their parental strains, the two G119V 189 mutant strains generated from different parents survived for longer. This is consistent with 190 the slower growth observed for these strains in the radial growth experiments. These strains 191 appear less fit than the wild type both in vitro and in vivo. 192

Evaluation of a large collection of clinical A. fumigatus isolates showed that the olorofim 195 resistance frequency is negligible and no cross resistance with azoles was detected. Olorofim resistance in A. fumigatus has not been reported before. A previous evolution 207 experiment involving 50 passages of A. fumigatus exposed to an olorofim concentration 208 gradient, resulted only in a modest olorofim MIC increase. In contrast voriconazole generated 209 a four-fold increase in MIC after only 15 passages (14). In the present study, we observed 210 the in vitro acquisition of olorofim resistance while screening for intrinsic resistance using an 211 agar supplemented with olorofim. All strains that were screened for olorofim resistance using 212 this method were inhibited on this olorofim-containing agar, except one isolate. The olorofim-213 containing agar well of this strain showed growth of a single colony, in contrast to the growth 214 control that showed confluent growth of numerous colonies on the whole agar surface. Had 215 the initial isolate been resistant, we would have also expected numerous colonies growing in 216 the olorofim-containing agar similar to the growth control. The lack of this growth, together 217 with the discrepant results from the susceptibility testing of the parental colony and the 218 colony growing on the olorofim-containing agar led us to believe that the resistant isolate had 219 acquired olorofim resistance while being cultured on olorofim-containing agar.

By using a high inoculum of 1x 10 9 CFU/mL we found that isolates with increased olorofim 221

MICs (> 8 mg/L) could indeed be selected confirming our previous observation. As we 222 wanted to understand the implications of this observation, we assessed the frequency of 223 resistance development of A. fumigatus to olorofim and compared this frequency to other 224 clinically used triazoles. We have chosen itraconazole and voriconazole as comparator 225 agents as resistance development has been described in patients receiving long-term 226 therapy for (cavitating) chronic pulmonary aspergillosis (CPA) but not in patients treated for 227 acute invasive aspergillosis (36, 37). We found that the resistance frequency of itraconazole 228 was higher than the resistance frequency found for voriconazole. Similar observations are 229 seen in the treatment of patients with CPA where the rate of emergence of azole resistance 230 during therapy was 13% for itraconazole and 5% for voriconazole (38) These experiments showed a small but significant reduction in growth rate for strains with a 287 G119V substitution (strain AZN8196_OLR1 and Af293_OLR9), while strains with a G119C 288 substitution did not exhibit a reduction in growth rate. These in vitro findings were confirmed 289 in the in vivo pathogenicity model whereas no significant difference in survival was observed 290 for isolates with a G119C amino acid substitution (isolates AZN8196_OLR2 and 291 Af293_OLR7). These results indicate that the amino acid substitution affects the binding of 292 olorofim to DHODH but may not affect the function of DHODH itself and the effect on 293 DHODH function is dependent on the underlying amino acid substitution. Furthermore, 294 compensatory evolution has been shown to occur in triazole-resistant A. fumigatus isolates 295 when cultured in azole-free conditions, indicating that a potential fitness cost can be 296 overcome (49). However, population dynamics such as competition with other (wildtype) 297 genotypes and selection pressure will ultimately determine which genotype will become 298

Olorofim represents an important new treatment option for patients with difficult to treat 300 invasive fungal infections, including triazole-resistant A. fumigatus infection. Our study 301 provides insights into one mechanisms and potential dynamics of olorofim resistance, which 302 will help to prevent and manage resistance selection in various patient groups. Such insights 303 are critical to antifungal stewardship and to safeguard its prolonged use in clinical practice. 0.05% tween 20 and the inoculum was transferred to a sterile vial. The spore suspension 332 was adjusted to 1x10 9 spores/mL using an hemocytometer. One mL spore suspension was added to a 90 mm agar plate containing RPMI 1640 +2% glucose (1.5% agar) containing 0.5 334 mg/L olorofim. Cultures were grown at 30°C. Isolates that grew on the olorofim containing 335 plates were subcultured on SAB-c for subsequent MIC testing and DNA isolation 336

Frequency of resistance analysis. Six A. fumigatus isolates (ATCC 204305, AZN8196, 337 V052-35 (TR34/L98H), V139-36, V180-37 and V254-51 were used for the olorofim resistance 338 induction experiment (Table 2) . SAB-c was inoculated using a single spore isolated from the 339 six parent strains and cultures were grown at 28°C. Spores were harvested in sterile saline 340 with 0.05% tween 20 and the inoculum was transported to a sterile vial. The spore 341 suspension was adjusted to 1x10 9 spores/mL using an hemocytometer. One mL spore 342 suspension was added to a 90 mm agar plate containing RPMI 1640 +2% glucose (15% 343 agar) containing either 0.5 mg/L olorofim, 4 mg/L voriconazole or itraconazole 8 mg/L. These 344 concentrations were chosen as these were the concentrations which are 2 dilutions higher 345 that the concentration that inhibits 100% of wildtype A. fumigatus isolates (51). Cultures were 346 grown at 30°C. Isolates that grew on the olorofim containing plates were subcultured on 347 SAB-c for subsequent MIC testing and DNA isolation. The resistance rate was calculated by 348 dividing the number of retrieved resistant colonies by the number of inoculated spores and 349 the mean of 5 experiments was used for comparison. Differences in resistance frequency 350 between olorofim and itraconazole or voriconazole were tested for significance using the 351 student T test. Statistical significance was defined as a P value of ≤0.05 (two-tailed). To 352 confirm the resistant rates, a second experiment was performed in another laboratory. Spore 353 stocks of A. fumigatus strain Af293 were prepared and inoculated onto yeast nitrogen base 354 with glucose agar (YNBG) containing 0.25 mg/L olorofim. A total of 8 x 10 9 spores were 355 inoculated into 12 x 100 ml YNBG-OLO agar plates that were subsequently incubated for 5 356 days at 35°C. Colonies growing on drug-containing plates were subcultured on YNBG-OLO 357 to confirm resistance. representing a linear version of pET44AFD with the mutation present was ligated using T4 377

Sequencing confirmed the desired mutations were present. The constructs were transformed 379 into E. coli BL21 (DE3) cells (Merck) and the mutant proteins were expressed and purified 380 according to the protocol described by Oliver, et al (14) . DHODH assays were set up in the 381 presence and absence of olorofim at concentrations between 0.008 to 100 µM. Assays were 382 carried out in 50 mM Tris HCl pH8, 150 mM KCl, 10% (wt/vol) glycerol, and 0.1% (wt/vol) 383

Triton X-100 in the presence of 1 mM L-dihydroorotic acid, 0.05 mM coenzyme Q2 and 0.1 384 mM 2,6-dichloroindophenol as a redox indicator. The reaction was followed by absorbance at 385 600 nm and reaction velocities used to construct IC50 curves. (14). Curves were fitted in 386

GraphPad Prism using variable slope (four parameters) on log transformed data.

To prove that G119 mutations are resulting in 388 increased olorofim MICs we introduced the G119C mutation in strain MFIG001 (34) as 389 previously described (33). In short, protoplasts were generated by inoculation of 390 approximately 1 x 10 6 fresh conidia in Yeast extract Glucose medium (YG; 0.5% yeast 391 extract, 2% glucose) for 16 hours at 37 °C shaking at 120 rpm. Mycelia were harvested by 392 filtration and resuspended in YG with protoplasting buffer (5 g Vinotaste in 50 mL 1M KCl 393 and 0.1 M Citric Acid added to 50 mL YG) and reincubated for 4 hours at 37 °C shaking at 394 100 rpm. Then protoplast were washed 3 times in 0.6 M KCl and 50 mM CaCl 2 and the 395 protoplast concentration was adjusted and diluted to approximately 1 x 10 6 protoplasts. A 396 PAM site close to the G119 locus was selected with an adjacent 20 nucleotide protospacer 397 that covers the G119 locus using a web-based guide RNA designing tool EuPaGDT 398 Radial growth rate. To study the radial growth rate we randomly selected five olorofim-420 resistant isolates, two from strain AZN8196 (AZN8196_OLR1, AZN8196_OLR2) and three 421 from strain Af293 (Af293_OLR5, Af293_OLR7, and Af293_OLR9) from the initial induction 422 experiments and compared the radial growth rate to the wildtype parent strain. The strains 423

were chosen as these strains harbored the most common amino acid substitutions G119C, 424 G119V and G119S. We assessed the growth by measuring the colony diameters in the 425 horizontal axis and vertical axis once every 24 hours for a period of 5 days. We used an 426 initial inoculum of 2 x 10 2 spores, quantified with an hemocytometer for all strains and 427 inoculated the spores in the middle of a 90mm petri dish with Yeast Nitrogen Base with 428 glucose. We did three independent experiments per strain and reported the mean of the 429 three experiments. Differences in growth rate in mm/day at day 5 between wildtype and 430

olorofim-resistant strains were tested for significance using the student T test. Statistical 431 significance was defined as a P value of ≤0.05 (two-tailed). 432 Af293_OLR5, Af293_OLR7, and Af293_OLR9. Mice were infected by intravenous 444 administration of 0.2mL conidial suspension. An inoculum of approximately 5 x 10 5 CFU/mL 445 was used for strains AZN8196, AZN8196_OLR1, AZN8196_OLR2 and an inoculum of 446 approximately 2 5 x 10 7 CFU/mL was used for strains Af293, Af293_OLR5, Af293_OLR7, 447 and Af293_OLR9 resulting in 1 x 10 5 CFU/mouse and 5 x 10 6 CFU/mouse respectively. 448

These inocula were chosen as those are the LD 90 doses that were previously determined for 449 these specific A. fumigatus strains (48, 52). The concentration of conidia was adjusted using 450 a hemocytometer and confirmed by quantitative culture on SDA. Actual and intended 451 inoculum levels are listed in table S1. Eight mice were inoculated with either strain. Mice 452 were monitored for survival for 10 days and euthanized when they demonstrated high weight 453 loss, signs of sepsis or severe torticollis. Survival data was analyzed using GraphPad Prism 454 (Version 5.3) and checked for significance using the Log-rank (Mantel-Cox) Test. Statistical 455 significance was defined as a P value of ≤0.05 (two-tailed). 456 

-5 x 10 5 1 x 10 5 5.05 x 10 5 1.01 x 10 5 68.13 -AZN8196_OLR1 G119V 5 x 10 5 1 x 10 5 4.10 x 10 5 8.20 x 10 4 89.75 P=0.0065 1 AZN8196_OLR2 G119C 5 x 10 5 1 x 10 5 3.40 x 10 5 6.80 x 10 4 73.38 NS 1 Af293 -2.5 x 10 7 5 x 10 6 2.15 x 10 7 4.30 x 10 6 45.25 -Af293_OLR5

G119S 2.5 x 10 7 5 x 10 6 2.05 x 10 7 4.10 x 10 6 46.75 NS 2 Af293_OLR7 G119C 2.5 x 10 7 5 x 10 6 2.55 x 10 7 5.10 x 10 6 48.25 NS 2 Af293_OLR9 G119V 2.5 x 10 7 5 x 10 6 1.35 x 10 7 2.70 x 10 6 55.00 P=0.0022 2 CFU: colony forming units. NS: not significant 477 

Global and multi-national prevalence of 520 fungal diseases-estimate precision

Invasive aspergillosis in patients 529 admitted to the intensive care unit with severe influenza: a retrospective cohort study

A national strategy to 534 diagnose COVID-19 associated invasive fungal disease in the ICU

Incidence of invasive 537 pulmonary aspergillosis among critically ill COVID-19 patients

Pulmonary aspergillosis in critically ill patients with Coronavirus 541 Disease 2019 (COVID-19)

Practice guidelines for the diagnosis and 545 management of aspergillosis: 2016 update by the Infectious Diseases Society of America

Diagnosis and 554 management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS 555 guideline

Azole resistance in Aspergillus 557 fumigatus: can we retain the clinical use of mold-active antifungal azoles?

Trends in Azole Resistance 560 in Aspergillus fumigatus, the Netherlands

Paradoxal trends in azole-resistant Aspergillus fumigatus in a national multicenter 564 surveillance program, the Netherlands

Voriconazole Resistance and Mortality 568

in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study

Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and 571 regulation of UMP biosynthesis

F901318 574 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase

Olorofim susceptibility 577 testing of 1423 Danish mould isolates 2018-2019 confirms uniform and broad-spectrum 578 activity

EUCAST Determination of Olorofim 583 (F901318) Susceptibility of Mold Species, Method Validation, and MICs

Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine 587 Models of Profound Neutropenia and Chronic Granulomatous Disease

In vitro activity of the novel antifungal 590 compound F901318 against difficult-to-treat Aspergillus isolates

In vitro activity of 593 olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and 594 CLSI methodologies

Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus 598 flavus

Pharmacodynamics of the 601 Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-602 Resistant Fungal Disease

In vitro activity of olorofim 604 (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as

Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus

Antibiofilm activity of 608 antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans

In vitro activity of 611 olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using 612 EUCAST and CLSI methodologies

Dihydroorotate dehydrogenase inhibitor F901318 has 614 potent in vitro activity against Scedosporium species and Lomentospora prolificans

In vitro 617 activity of the novel antifungal compound F901318 against Australian Scedosporium and 618 Lomentospora fungi

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous 621 System Coccidioidomycosis

Sande 623 W. 2020. Madurella mycetomatis, the main causative agent of eumycetoma, is highly 624 susceptible to olorofim

Review of the Novel Investigational Antifungal Olorofim

Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising 629 activity against all clinically relevant species within Aspergillus section Terrei

Development of a 635 marker-free mutagenesis system using CRISPR-Cas9 in the pathogenic mould Aspergillus 636 fumigatus. Fungal genetics and biology

On the 638 lineage of Aspergillus fumigatus isolates in common laboratory use

Development of azole resistance in Aspergillus fumigatus during azole 641 therapy associated with change in virulence

Frequency and evolution of Azole resistance in 644

Aspergillus fumigatus associated with treatment failure

In-host 646 microevolution of Aspergillus fumigatus: A phenotypic and genotypic analysis

Twelve-month clinical 649 outcomes of 206 patients with chronic pulmonary aspergillosis

Molecular Tools for the Detection and Deduction of Azole Antifungal Drug 652 Resistance Phenotypes in Aspergillus Species

Azole resistance in 654

Aspergillus fumigatus: a side-effect of environmental fungicide use?

Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus

The URA5 gene is 660 necessary for histoplasma capsulatum growth during infection of mouse and human cells

Strains and strategies for large-scale gene deletion studies of 663 the diploid human fungal pathogen Candida albicans

The 665 role of the de novo pyrimidine biosynthetic pathway in Cryptococcus neoformans high 666 temperature growth and virulence

In vitro 668 acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged 669 exposure to itraconazole: presence of heteroresistant populations

In vitro evolution 673 of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of 674 resistance

The Aspergillus fumigatus chsC 676 and chsG genes encode class III chitin synthases with different functions

Correlation between in vitro growth rate and in 679 vivo virulence in Aspergillus fumigatus

In-host adaptation and acquired triazole resistance in Aspergillus 682 fumigatus: a dilemma for clinical management

Comparative and collaborative evaluation of standardization 685 of antifungal susceptibility testing for filamentous fungi

Center Evaluation of an Agar-Based Screening for Azole Resistance in Aspergillus fumigatus 689 by Using VIPcheck

Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two 692

Different Immunosuppression Models of Invasive Aspergillosis